Site Search:
2014 Press Releases
Keyword Search
 
2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
08/12/14GenVec Reports Second Quarter 2014 Financial Results
GAITHERSBURG, Md., Aug. 12, 2014 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the three-month and six-month periods ended June 30, 2014. For the three-month period ended June 30, 2014, the company reported a net loss of $1.7 million or $0.10 per share on revenues of $0.1 million as compared to a net loss of $3.1 million or $0.24 per share on revenues of $0.7 million in the same period in the prior year. For the six-month period ended June 30, 2014, the company... 
Printer Friendly Version
05/12/14GenVec Reports First Quarter 2014 Financial Results
GAITHERSBURG, Md., May 12, 2014 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the first quarter ended March 31, 2014. For the three months ended March 31, 2014, the company reported a net loss of $1.0 million, or $0.07 per share on revenues of $2.1 million compared with a net loss of $3.0 million, or $0.24 per share on revenues of $1.2 million, for the same period in the prior year. GenVec ended the first quarter of 2014 with $15.3 million in cash, cash equival... 
Printer Friendly Version
03/28/14GenVec Reports Fourth Quarter and 2013 Year-End Financial Results
GAITHERSBURG, Md., March 28, 2014 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the fourth quarter and year ended December 31, 2013. For the year ended December 31, 2013, the company reported a net loss of $10.0 million, or $0.77 per share, compared with a net loss of $14.1 million, or $1.09 per share, for the year ended December 31, 2012. GenVec ended the year with $6.1 million in cash, cash equivalents, and short-term investments.  "Over the past six mont... 
Printer Friendly Version
03/21/14GenVec To Release Fourth Quarter And Year-End 2013 Financial Results And Conduct A Conference Call On March 28, 2014
GAITHERSBURG, Md., March 21, 2014 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC) will report financial results for the fourth quarter and year ended December 31, 2013 on Friday, March 28, 2014, before the U.S. financial markets open. The announcement will be followed by a webcast and conference call at 10:00 a.m. EDT to discuss the company's fourth quarter and 2013 financial results as well as recent highlights and the 2014 business outlook. To listen to the live conference call, please dial 87... 
Printer Friendly Version
03/13/14GenVec Announces $9 Million Registered Direct Offering
GAITHERSBURG, Md., March 13, 2014 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC) ("GenVec") today announced it has agreed to sell approximately $9 million of shares of its common stock to selected institutional investors in a registered direct offering at a price of $3.15 per share. In the offering, GenVec will issue approximately 2,870,000 shares of its common stock. The closing of the offering is expected to take place on or about March 18, 2014, subject to the satisfaction of customary closing c... 
Printer Friendly Version
03/03/14GenVec to Present at 26th Annual ROTH Conference
GAITHERSBURG, Md., March 3, 2014 /PRNewswire/ -- GenVec, Inc. (NASDAQ:GNVC) announced today that the Company will participate in the 26th Annual ROTH Conference being held March 9-12, 2014 in Dana Point, California. Douglas Swirsky, President and CEO of GenVec, will present a company overview on Monday, March 10, 2014 at 3:00 pm Pacific Daylight Time. A webcast of Mr. Swirsky's presentation will be available both live and on replay. The presentation will be available via webcast at http://wsw... 
Printer Friendly Version
02/13/14GenVec Achieves Third Milestone In Hearing And Balance Collaboration
GAITHERSBURG, Md., Feb. 13, 2014 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC) today announced that the company has achieved the third milestone in its collaboration with Novartis for the development of treatments for hearing and balance disorders.  In January 2014, Novartis filed an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) for the clinical development of CGF166, the lead product candidate under the collaboration.  The IND was deemed effective on Febru... 
Printer Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
GNVC (Common)
ExchangeNASDAQ CM (US Dollar)
Price$1.71
Change (%) Stock is Up 0.01 (0.59%)
Volume12,054
Data as of 10/16/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Print This Page | Bookmark this Page
home